Our Company
About Us
Our Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Strategy
Scientific Platform
Therapeutic Areas
Manufacturing
Research & Development
Pipeline
Clinical Trials
Posters & Publications
Patients & Families
Investors & Media
Overview
News Releases
Events & Presentations
Stock Information
Corporate Governance
Financial Information
Investor Resources
Join Our Team
Efficacy assessment and pre-clinical toxicology of AAV2/8-hCARp.hCNGB3, a CNGB3 gene therapy vector.